Orbis Medicines

Series-A
orbismedicines.com Biotech & Healthcare Copenhagen, Denmark 1–10 employees
Total Funding $121M
Latest Round $93M Series-A
Last Announced Jan 6, 2025
Investors 7 Backers
Decision Makers 4 Available

About Orbis Medicines

Orbis Medicines is a novel macrocyclic chemistry and computational platform for oral macrocycle drug discovery.

Company Details

Intelligence Dossier

Corporate & Operational Profile

Primary Industry Biotech & Healthcare
Funding Stage Series-A
Global Headquarters Copenhagen, Denmark
Team Size 1–10 employees
Tracked Since Nov 8, 2026

Web & Domain Identity

Official Website orbismedicines.com
Domain Registered Date Undisclosed

Social & Network Presence

X / Twitter Profile Not linked
LinkedIn Corporate Company Profile

Company Milestones & Timeline

2 Events
  1. Capital Raise

    Raised $93,000,000 · Series-A

    Backed by NEA

  2. Capital Raise

    Raised $28,000,000 · Seed

    Backed by Forbion Capital Partners

Investors & Backers

7
Forbion Capital Partners
Lead
NEA
Lead
Cormorant Asset Management
Eli Lilly
Export and Investment Fund
Novo Holdings
Novo Nordisk

Funding History

2 Rounds
Series-A equity · Jan 6, 2025

Round backers: NEA

Seed equity · Feb 1, 2024

Round backers: Forbion Capital Partners

Founders & Leadership

5

Daniela Brodbeck

VP Discovery Biology and Operations

Work email & phone locked Unlock →

Mikkel Dybkjær

CFO/COO

Work email & phone locked Unlock →

Morten Graugaard Døssing

CEO

Work email & phone locked Unlock →

Sevan Habeshian

Founder

Work email & phone locked Unlock →

Simon Nielsen

Chief Development Officer

Work email & phone locked Unlock →

Press Coverage & Sources

Recently Funded Biotech & Healthcare Startups

View all

Search the startup feeds free with 50 starter credits.

Recently funded startups
New SaaS launches
Never pay twice for contacts